BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jardiance (Empagliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Jardiance (Empagliflozin)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05057806-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT05057806)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1\, Type 2 Diabetes.\nStudy: 
 SGLT2 Inhibitors\, Ketones\, and Cardiovascular Benefit Research Plan\nEst
 imated primary completion: 30 November 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05057806
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06030843-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Jardiance (Empagliflozin): Phase 2/3 readout est. (NCT06030843)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2/3.\nStudy: The Treatment Ef
 fects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1\nE
 stimated primary completion: 30 November 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06030843
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06554301-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT06554301)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1.\nStudy: A Study on the Eff
 icacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial H
 ypertension\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06554301
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: 
 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With 
 Type 2 Diabetes on a Background of Alogliptin and Metformin\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07093476
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07311551-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07311551)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 A Comparison of Effectiveness\, Safety\, and Cost-effectiveness of Dapagli
 flozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and Hig
 h Body Mass Index (BMI)\nEstimated primary completion: December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07311551
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07692256-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07692256)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: th
 e Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07692256
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05726032-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT05726032)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Empagliflozin in P
 atients With Cirrhosis and Ascites\nEstimated primary completion: 1 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 726032
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845630-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261211
DTEND;VALUE=DATE:20261212
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT07845630)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1.\nStudy: A Study in Healthy
  People to Compare How 2 Different Formulations of Vicadrostat / Empaglifl
 ozin Tablets Are Taken up in the Body\nEstimated primary completion: 11 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empaglif
 lozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07845630
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336797-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07336797)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Effect of Empaglif
 lozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegrav
 ir-Based Therapy\nEstimated primary completion: 30 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07336797
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786443-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT05786443)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Chronic Kidney Disease.\n
 Study: Safety and Efficacy of Empagliflozin in Hemodialysis\nEstimated pri
 mary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05786443
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700940-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07700940)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: The Efficacy of Em
 pagliflozin on Kidney Functions in Lupus Nephritis Population\nEstimated p
 rimary completion: 30 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07700940
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05392764-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05392764)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: Ea
 rly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-ris
 k Patients With Acute Heart Failure\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflo
 zin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05392764
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989723-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06989723)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06989723
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05164263-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT05164263)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Real World Safety & Efficacy Experience of Empagliflozin With or Without M
 etformin in T2DM Patients - EASE Study\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05164263
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055452-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06055452)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Heart Failure.\nStudy: Ef
 fects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertensi
 on\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06055452
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671991-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT05671991)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Chronic Kidney Disease.\n
 Study: Effect of Empagliflozin on Peritoneal and Kidney Function in End St
 age Renal Disease\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05671991
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260059-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06260059)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Heart Failure.\nStudy: Ef
 ficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients 
 With Congenital Heart Disease\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062600
 59
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519448-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase na readout est. (NCT06519448)
DESCRIPTION:Jardiance (Empagliflozin)\, phase na\, Type 2 Diabetes.\nStudy:
  Reducing Non-Alcoholic Steatohepatitis\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagl
 iflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06519448
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894784-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06894784)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: A Clinical Trial t
 o Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automa
 ted Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diab
 etes\nEstimated primary completion: January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06894784
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372040-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07372040)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Ad
 d-on Diuretics in Acute Decompensated Heart Failure\nEstimated primary com
 pletion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07372040
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06473844-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Jardiance (Empagliflozin): Phase na readout est. (NCT06473844)
DESCRIPTION:Jardiance (Empagliflozin)\, phase na.\nStudy: Efficacy of SGLT2
  Inhibitors in Adults With Sepsis\nEstimated primary completion: 28 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 473844
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05879276-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05879276)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Effect at 3 Months
  of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortal
 ity\, Rehospitalization\, Left Ventricular Ejection Fraction and Renal Fun
 ction.\nEstimated primary completion: 16 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05879276
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643442-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06643442)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Repurposing Empagl
 iflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06643442
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570473-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06570473)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Fe
 asibility Trial for a Right Ventricular Failure Platform Trial\nEstimated 
 primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06570473
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442006-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07442006)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Glycemic Variability of Combination Therapies in T2DM\nEstimated primary c
 ompletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07442006
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947706-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Jardiance (Empagliflozin): Phase 1/2 readout est. (NCT07947706)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1/2.\nStudy: Chronic HBV Pati
 ents With Hepatic Steatosis : Clinical and Portal Doppler Outcomes.\nEstim
 ated primary completion: 1 April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07947706
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107945-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07107945)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps 
 Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)\
 nEstimated primary completion: 16 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07107945
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038356-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07038356)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: Ef
 fects of Continued Administration of Empagliflozin in Patients With Heart 
 Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensat
 ed Heart Failure\nEstimated primary completion: 30 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07038356
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678151-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Jardiance (Empagliflozin): Phase na readout est. (NCT07678151)
DESCRIPTION:Jardiance (Empagliflozin)\, phase na.\nStudy: Finerenone and Em
 pagliflozin Combination in Obesity With Hypertension: A 12-Week Prospectiv
 e\, Parallel-design\, Double-blind\, Randomized\, Placebo-controlled Trial
 \nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07678151
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06391450-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06391450)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: Study of Empaglifl
 ozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-P
 KD)\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06391450
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05715814-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05715814)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Chronic Kidney Disease.\n
 Study: meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis\nE
 stimated primary completion: 1 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05715814
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05138575-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT05138575)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: SG
 LT2i and KNO3 in HFpEF - The SAK HFpEF Trial\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagl
 iflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05138575
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06729996-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06729996)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Pioglitazone Versu
 s Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acut
 e Pancreatitis Associated Diabetes Mellitus\nEstimated primary completion:
  31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06729996
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898709-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07898709)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Evaluating SGLT2 Inhibitors for the Reduction of No
 -Reflow Phenomenon in Patients Undergoing PCI\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagli
 flozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07898709
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053306-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT07053306)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1\, Type 2 Diabetes.\nStudy: 
 SGLT2i\, Ketoacidosis\, Volume Contraction\, and Insulinopenia\nEstimated 
 primary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07053306
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053319-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT07053319)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1\, Type 2 Diabetes.\nStudy: 
 SGLT2i\, Pioglitazone\, and Ketone Production in T2D\nEstimated primary co
 mpletion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07053319
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05960656-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT05960656)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1\, Type 2 Diabetes.\nStudy: 
 SGLTi\, Hepatic Glucose Production and Ketogenesis\nEstimated primary comp
 letion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 empagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05960656
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053293-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT07053293)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1\, Type 2 Diabetes.\nStudy: 
 SGLT2i\, Hepatic Glucose Production\, and SNS\nEstimated primary completio
 n: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empag
 liflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07053293
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972564-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jardiance (Empagliflozin): Phase 1/2 readout est. (NCT05972564)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1/2.\nStudy: The Effect of SG
 LT2 Inhibition on Adipose Inflammation and Endothelial Function\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05972564
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292909-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07292909)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Effect of Empagliflozin on Inflammation\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07292909
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06446531-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT06446531)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1.\nStudy: Prevention of Prog
 ression of Prediabetes\, Obesity and CV Risk\nEstimated primary completion
 : July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empaglif
 lozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06446531
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528405-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06528405)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: The Efficacy and S
 afety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute 
 Kidney Disease\nEstimated primary completion: July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06528405
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155694-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07155694)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Chronic Kidney Disease.\n
 Study: Role of Finerenone in African American Veterans With Diabetic Kidne
 y Disease\nEstimated primary completion: July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07155694
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06483074-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06483074)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Chronic Kidney Disease.\n
 Study: Empagliflozin on Residual Kidney Function in Incident Peritoneal Di
 alysis Patients\nEstimated primary completion: 31 July 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06483074
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365358-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07365358)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combinati
 on Therapy in Type 2 Diabetes Mellitus Patients\nEstimated primary complet
 ion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/emp
 agliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07365358
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472920-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Jardiance (Empagliflozin): Phase na readout est. (NCT07472920)
DESCRIPTION:Jardiance (Empagliflozin)\, phase na.\nStudy: Empagliflozin Adj
 unctive Therapy in Bipolar Depression\nEstimated primary completion: Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 72920
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776054-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07776054)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: Clinical Impact of
  SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF\nEstim
 ated primary completion: 1 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07776054
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146880-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270821
DTEND;VALUE=DATE:20270822
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07146880)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Empagliflozin as a
  Potential Therapeutic Solution for Patients With Brugada Syndrome\nEstima
 ted primary completion: 21 August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07146880
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141355-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Jardiance (Empagliflozin): Phase na readout est. (NCT07141355)
DESCRIPTION:Jardiance (Empagliflozin)\, phase na.\nStudy: Empagliflozin's M
 icrocirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of 
 the EMPASHOCK Trial\nEstimated primary completion: 31 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07141355
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06613854-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06613854)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Effect of Early Combination Antihyperglycemic Treatment on Metabolic Contr
 ol in Individuals With Type 2 Diabetes\nEstimated primary completion: Sept
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empaglifl
 ozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06613854
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749014-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07749014)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Timing of Empagliflozin in Primary PCI: Pre-Reperfu
 sion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients\
 nEstimated primary completion: 30 September 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07749014
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883512-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07883512)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: EMBRACE (EMPA in B
 Reast Cancer for Activity and Cardiac ProtEction)\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07883512
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06024746-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06024746)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Heart Failure.\nStudy: A 
 Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Com
 bination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)\nEs
 timated primary completion: November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06024746
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07864688-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07864688)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Evaluation of Dapa
 gliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patie
 nts With Rheumatoid Arthritis\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07864688
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955260-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06955260)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: SGLT2 Inhibition W
 ith Empagliflozin in Fontan Circulatory Failure\nEstimated primary complet
 ion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 mpagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06955260
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06110130-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06110130)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Chronic Kidney Disease.\n
 Study: Effect of Empagliflozin on Podocyte Specific Proteins in African Am
 erican Veterans With NDKD\nEstimated primary completion: 1 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06110130
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06249945-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06249945)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Heart Failure.\nStudy: EM
 PAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stag
 e Renal Disease\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06249945
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05147090-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT05147090)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: Effects of Empagli
 flozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05147090
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771010-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07771010)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microv
 ascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mel
 litus\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07771010
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06249932-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06249932)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Heart Failure.\nStudy: Em
 pagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage 
 Renal Disease\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06249932
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03867487-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT03867487)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: SGLT2 Inhibitors a
 s a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease\nEstim
 ated primary completion: 1 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03867487
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06355310-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06355310)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Mechanisms of SGLT
 2 Inhibition in Pediatric Steatotic Liver Disease\nEstimated primary compl
 etion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06355310
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05271162-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT05271162)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Empagliflozin in t
 he Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy
  Based on Anthracyclines\nEstimated primary completion: 1 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05271162
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304817-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07304817)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Heart Failure.\nStudy: Co
 mparative Study on the Mode of Action of Vicadrostat and Spironolactone on
  Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)\nEstimated pr
 imary completion: February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07304817
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06674109-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06674109)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: SAVE-Care (Sodium 
 Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial\nEst
 imated primary completion: 1 February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06674109
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756294-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07756294)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Restoring Vascular
  and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disea
 se\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07756294
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07074418-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07074418)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Chronic Kidney Disease.\n
 Study: Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/
 Min/1.73m2\nEstimated primary completion: May 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07074418
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07799441-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07799441)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: Neurovascular Effe
 cts of Empagliflozin\nEstimated primary completion: September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07799441
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT04381936)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Randomised Evaluat
 ion of COVID-19 Therapy\nEstimated primary completion: 30 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04381936
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815808-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07815808)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Cardioprotective E
 ffect of Empagliflozin in Breast Cancer Patients\nEstimated primary comple
 tion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07815808
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506422-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Jardiance (Empagliflozin): Phase 2/3 readout est. (NCT06506422)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2/3.\nStudy: Empagliflozin Re
 versal of Arterial StiffnEss in Aging\nEstimated primary completion: 31 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empaglifl
 ozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06506422
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055282-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT07055282)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1.\nStudy: SGLT2i in Kidney S
 tones\nEstimated primary completion: 1 November 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07055282
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228195-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07228195)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: SGLT2i Therapy in 
 Islet Transplantation (SIT)\nEstimated primary completion: 1 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07228195
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745063-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06745063)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Arterial Destiffen
 ing Effects of SGLT2 Inhibition in Veterans With Obesity\nEstimated primar
 y completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06745063
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642272-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06642272)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluste
 r Randomization Embedded in the Electronic Health Record\nEstimated primar
 y completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06642272
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06507657-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Jardiance (Empagliflozin): Phase 1 readout est. (NCT06507657)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1\, Heart Failure.\nStudy: Ef
 fect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart 
 Failure\nEstimated primary completion: 15 January 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06507657
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322237-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07322237)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: DICE Study- Diasto
 lic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
 \nEstimated primary completion: 30 January 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07322237
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775846-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07775846)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Chronic Kidney Disease.\n
 Study: QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy\nEst
 imated primary completion: 28 February 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07775846
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828002-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Jardiance (Empagliflozin): Phase 2/3 readout est. (NCT07828002)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2/3.\nStudy: The GranStone Tr
 ial\nEstimated primary completion: March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07828002
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060417-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07060417)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2\, Chronic Kidney Disease.\n
 Study: Vascular Effects of SGLT2i in Non-diabetic CKD\nEstimated primary c
 ompletion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07060417
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT07547878)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies
  (RAPID-CKD)\nEstimated primary completion: 31 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06625073-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06625073)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4.\nStudy: Randomized Trial o
 f SGLT2i in Heart Transplant Recipients\nEstimated primary completion: 31 
 August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/empaglif
 lozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06625073
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175051-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT07175051)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Targeting the Path
 ophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibito
 rs\, Empagliflozin\nEstimated primary completion: October 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07175051
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06013865-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Jardiance (Empagliflozin): Phase 4 readout est. (NCT06013865)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 4\, Chronic Kidney Disease.\n
 Study: Empagliflozin Treatment in Kidney Transplant Recipients\nEstimated 
 primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06013865
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992440-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Jardiance (Empagliflozin): Phase 2 readout est. (NCT06992440)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 2.\nStudy: Empagliflozin to I
 mprove Right Ventricular Function in Pulmonary Arterial Hypertension\nEsti
 mated primary completion: July 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06992440
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06653738-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT06653738)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: Trial to Assess th
 e Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney
  STONE Prevention\nEstimated primary completion: September 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/empagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06653738
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Jardiance (Empagliflozin): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 1/2.\nStudy: A Study Evaluati
 ng the Efficacy and Safety of Multiple Treatment Combinations in Patients 
 With Metastatic or Locally Advanced Breast Cancer\nEstimated primary compl
 etion: 30 September 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533747-308@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07533747)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3.\nStudy: PRECISE Phenotypin
 g to Guide Therapies for Coronary Microvascular Dysfunction\nEstimated pri
 mary completion: May 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/empagliflozin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07533747
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
